TY - JOUR
T1 - Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression
AU - Lee, Eung Sirk
AU - Son, Dae Soon
AU - Kim, Sung Hyun
AU - Lee, Jinseon
AU - Jo, Jisuk
AU - Han, Joungho
AU - Kim, Heesue
AU - Hyun, Joo Lee
AU - Hye, Young Choi
AU - Jung, Youngja
AU - Park, Miyeon
AU - Yu, Sung Lim
AU - Kim, Kwhanmien
AU - Young, Mog Shim
AU - Byung, Chul Kim
AU - Lee, Kyusang
AU - Huh, Nam
AU - Ko, Christopher
AU - Park, Kyunghee
AU - Jae, Won Lee
AU - Yong, Soo Choi
AU - Kim, Jhingook
PY - 2008/11/15
Y1 - 2008/11/15
N2 - Purpose: One of the main challenges of lung cancer research is identifying patients at high risk for recurrence after surgical resection. Simple, accurate, and reproducible methods of evaluating individual risks of recurrence are needed. Experimental Design: Based on a combined analysis of time-to-recurrence data, censoring information, and microarray data from a set of 138 patients, we selected statistically significant genes thought to be predictive of disease recurrence. The number of genes was further reduced by eliminating those whose expression levels were not reproducible by real-time quantitative PCR. Within these variables, a recurrence prediction model was constructed using Cox proportional hazard regression and validated via two independent cohorts (n = 56 and n = 59). Results: After performing a log-rank test of the microarray data and successively selecting genes based on real-time quantitative PCR analysis, the most significant 18 genes had P values of <0.05. After subsequent stepwise variable selection based on gene expression information and clinical variables, the recurrence prediction model consisted of six genes (CALB1, MMP7, SLC1A7, GSTA1, CCL19, and IFI44). Two pathologic variables, pStage and cellular differentiation, were developed. Validation by two independent cohorts confirmed that the proposed model is significantly accurate (P = 0.0314 and 0.0305, respectively). The predicted median recurrence-free survival times for each patient correlated well with the actual data. Conclusions: We have developed an accurate, technically simple, and reproducible method for predicting individual recurrence risks. This model would potentially be useful in developing customized strategies for managing lung cancer.
AB - Purpose: One of the main challenges of lung cancer research is identifying patients at high risk for recurrence after surgical resection. Simple, accurate, and reproducible methods of evaluating individual risks of recurrence are needed. Experimental Design: Based on a combined analysis of time-to-recurrence data, censoring information, and microarray data from a set of 138 patients, we selected statistically significant genes thought to be predictive of disease recurrence. The number of genes was further reduced by eliminating those whose expression levels were not reproducible by real-time quantitative PCR. Within these variables, a recurrence prediction model was constructed using Cox proportional hazard regression and validated via two independent cohorts (n = 56 and n = 59). Results: After performing a log-rank test of the microarray data and successively selecting genes based on real-time quantitative PCR analysis, the most significant 18 genes had P values of <0.05. After subsequent stepwise variable selection based on gene expression information and clinical variables, the recurrence prediction model consisted of six genes (CALB1, MMP7, SLC1A7, GSTA1, CCL19, and IFI44). Two pathologic variables, pStage and cellular differentiation, were developed. Validation by two independent cohorts confirmed that the proposed model is significantly accurate (P = 0.0314 and 0.0305, respectively). The predicted median recurrence-free survival times for each patient correlated well with the actual data. Conclusions: We have developed an accurate, technically simple, and reproducible method for predicting individual recurrence risks. This model would potentially be useful in developing customized strategies for managing lung cancer.
UR - https://www.scopus.com/pages/publications/58149343905
U2 - 10.1158/1078-0432.CCR-07-4937
DO - 10.1158/1078-0432.CCR-07-4937
M3 - Article
C2 - 19010856
AN - SCOPUS:58149343905
SN - 1078-0432
VL - 14
SP - 7397
EP - 7404
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 22
ER -